NAD+ Injections vs Peptides: A Coenzyme Is Not an Amino-Acid Chain
NAD+ injections are a coenzyme therapy, not a peptide. Structure, legal status and evidence, compared side by side with the peptides they get sold alongside.
The short version
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme built from two nucleotides, not a chain of amino acids, so it is not a peptide by any chemical definition. Longevity and IV-therapy clinics market it alongside research peptides, but the molecules, evidence and regulatory status differ.
- NAD+ is a dinucleotide coenzyme. A peptide is a chain of amino acids. The building blocks differ.
- "Peptide" is not one category: the peptides compared here span prescription, cosmetic and research buckets.
- NAD+ has its own compounding problem: FDA warned one IV-therapy compounder over it in January 2026.
NAD+ vs peptides is not a contest between two things in the same category. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme built from two nucleotides. A peptide is a chain of amino acids. They show up on the same clinic menu and the same longevity blogs, and that proximity is the source of the confusion. See is NAD+ a peptide? for the full chemistry answer. This page compares the molecules, the evidence and the regulatory status side by side.
What NAD+ actually is
NAD+ is short for nicotinamide adenine dinucleotide. It is a dinucleotide: two nucleotides, one built on nicotinamide and one on adenine, joined through a pair of phosphate groups. PubChem lists its molecular formula as C21H27N7O14P2 and its molecular weight as 663.4 g/mol.
It is a coenzyme. Cells use it as an electron carrier in redox reactions and as a substrate for enzymes including sirtuins and PARPs. None of that chemistry involves amino acids or peptide bonds.
What a peptide actually is
A peptide is a short chain of amino acids joined by peptide bonds. That chemistry fact is all “peptide” means. It says nothing about whether a given peptide is a supermarket supplement, an FDA-approved medicine or an unapproved research chemical. My full explainer covers the three buckets this site uses. The peptides in the table below were picked to show that range, not because they are the closest chemical relatives of NAD+. Nothing on this page is.
Side by side
| NAD+ | Semaglutide | BPC-157 | GHK-Cu | |
|---|---|---|---|---|
| Chemical class | Dinucleotide coenzyme | Peptide (GLP-1 analogue) | Synthetic peptide (15 aa) | Copper tripeptide (3 aa) |
| Built from | Two nucleotides + phosphates | Amino acids | Amino acids | Amino acids + copper ion |
| Bucket on this site | No compound bucket assigned - IV/injectable use sits outside all three | Prescription (rx) | Research | Cosmetic (clean) |
| US legal status | Unapproved for the injectable/IV use it is sold for | FDA-approved (Ozempic, Wegovy, Rybelsus) | Research use only, not for human use | Cosmetic ingredient, no pre-market approval needed |
| Typical route sold | IV infusion or injection, also oral precursors | Weekly injection or daily tablet | Self-injected or oral, vendor-dependent | Topical serum |
| Human clinical trials behind it | None located for the IV/injectable product | Multiple, reviewed by FDA for three separate approvals | None indexed under a clinical-trial publication type | Small studies; flagship human data mostly unpublished as peer-reviewed papers |
Full pages: What are peptides? · Semaglutide · BPC-157 · GHK-Cu
NAD+‘s own compounding problem
US legal status - Unapproved drug
Not approved by the FDA as a drug for any use. NAD+ does not appear on FDA's 503B bulks list, so an outsourcing facility compounding it in bulk is not doing so lawfully.
This is separate from anything on a peptide’s page. In a warning letter dated 20 January 2026, FDA told compounder GenoGenix LLC that it had compounded drug products using NAD+. NAD+ is a bulk drug substance not eligible for use in compounding under section 503B. Three patients developed low blood pressure, uncontrollable shaking, shivers and body aches during or shortly after administration of NAD+ from the same lot. They were sent to the emergency room. Testing of that lot found excessive bacterial endotoxins.
That is one compounder, not a verdict on every NAD+ product sold. It does establish the baseline: injectable and IV NAD+ is not an approved drug. FDA has already acted against at least one firm compounding it outside the rules that govern bulk drug substances.
Where each peptide sits
US legal status - FDA-approved · prescription only
Semaglutide is FDA-approved as Ozempic, Wegovy and Rybelsus, each with its own label and indication.
Semaglutide is the closest thing to a settled case here: three FDA approvals, reviewed on placebo-controlled trials. Full detail on the semaglutide page.
US legal status - Research use only
Sold for laboratory research use only; not approved by the FDA for human use.
BPC-157 sits at the other end. Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references below reports the majority of the literature is rodent work, and Józwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2)., in the references below states it has not been approved due to the absence of sufficient clinical studies. Full detail on the BPC-157 page.
US legal status - Cosmetic
Regulated as a cosmetic ingredient in the US; may only make appearance claims.
GHK-Cu is a cosmetic ingredient, not a drug claim. Full detail on the GHK-Cu page.
Where NAD+ and a peptide share a page
The two molecules intersect in one place: 5-Amino-1MQ. It is a research compound, not a peptide itself, studied for inhibiting an enzyme (NNMT) implicated in cellular NAD+ turnover. That is a proposed mechanism from cell-culture and rodent work, not a demonstrated effect in people. The connection runs through an enzyme, not through NAD+ and the peptide sharing a structure.
Related
- Best NAD+ supplement: NR, NMN and niacin products compared
- Is NAD+ a peptide?
- What are peptides?
- 5-Amino-1MQ
- Semaglutide · BPC-157 · GHK-Cu
- Compounds index
Common questions
Is NAD+ a peptide?
No. NAD+ is nicotinamide adenine dinucleotide, a coenzyme built from two nucleotides joined by a pair of phosphate groups. A peptide is a chain of amino acids joined by peptide bonds. They are built from different chemical building blocks, and neither is a form of the other.
Is NAD+ IV therapy FDA-approved?
No. NAD+ does not appear on FDA's list of bulk drug substances eligible for outsourcing-facility compounding under section 503B. In a warning letter dated 20 January 2026, FDA told compounder GenoGenix LLC that its NAD+ products were unapproved new drugs. Three patients had needed emergency treatment for low blood pressure, uncontrollable shaking, shivers and body aches after an NAD+ infusion, and testing found excessive bacterial endotoxins in the product.
Are NAD+ and peptides used for the same thing?
They overlap in marketing more than in chemistry. Both appear in longevity and wellness clinics alongside claims about energy, ageing and recovery. The peptides compared on this page span three regulatory buckets (a prescription medicine, a cosmetic ingredient and a research chemical), and NAD+ sits in a compounding dispute of its own. Being sold in the same clinic is not evidence that two molecules do the same thing.
Does the body make peptides out of NAD+, or NAD+ out of peptides?
No. NAD+ is a coenzyme used in redox reactions and as a substrate for enzymes including sirtuins and PARPs. It is not assembled from amino acids and is not converted into a peptide chain. They are unrelated classes of molecule that happen to be marketed in the same corner of the supplement and research-chemical market.
Is NAD+ like Ozempic?
No. Ozempic (semaglutide) is an FDA-approved GLP-1 receptor agonist, a peptide, prescribed for type 2 diabetes and, as Wegovy, for chronic weight management. NAD+ is a dinucleotide coenzyme, not a peptide, and no injectable or IV NAD+ product has that kind of FDA approval. They get grouped together because both show up on the same weight and longevity clinic menus, not because they work the same way.
What is the downside of taking NAD+?
The clearest documented downside is regulatory and safety, not a mild side effect. Injectable and IV NAD+ is not an FDA-approved drug for any use. In a warning letter dated 20 January 2026, FDA told compounder GenoGenix LLC about three patients who needed emergency treatment. They had low blood pressure, uncontrollable shaking, shivers and body aches after an NAD+ infusion. The tested lot contained excessive bacterial endotoxins. Outside that one enforcement action, there is no FDA-reviewed safety database for injectable NAD+, as there is for an approved drug. Cost is a separate downside: because no injectable NAD+ product is FDA-approved, insurance does not reimburse it, and clinics set their own per-session pricing.
Is NAD+ like Adderall?
No. Adderall is an FDA-approved Schedule II controlled substance, a combination of amphetamine salts, indicated for ADHD and narcolepsy. It requires a prescription because of its abuse potential. NAD+ is a coenzyme, not a stimulant and not a controlled substance, and no injectable NAD+ product is FDA-approved at all. Both get marketed for energy and focus, which is the extent of the overlap.
Will NAD+ help with ADHD?
I found no clinical evidence for that use. NAD+ is not FDA-approved for ADHD or any other condition. Adderall has been through controlled trials reviewed by FDA specifically for ADHD. NAD+ has not been through that process for any indication.
What are Adderall eyes?
"Adderall eyes" is the informal name for the pupil dilation (mydriasis) that Adderall's FDA label lists as a reported eye-related adverse reaction. It is a stimulant side effect of amphetamine medications. It is not linked to NAD+ or to any peptide compared on this page.
What does the NAD injection do?
It delivers NAD+, a coenzyme cells use to carry electrons in energy metabolism and as fuel for enzymes such as sirtuins and PARPs. No outcome trial has shown what the injection does for health. Infused NAD+ was cleared from the blood quickly in a small pilot study. A systematic review found no outcome trials of intravenous or intramuscular NAD+ for anti-ageing or wellness. No injectable NAD+ product is FDA-approved. More at /nad-injection/.
References (5 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
- 2.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
- 3.PubChem CID 5892 - Nicotinamide adenine dinucleotide (NAD), computed molecular formula and molecular weight.- PubChem, National Center for Biotechnology Information, US National Library of Medicinedatabase
- 4.FDA warning letter to GenoGenix LLC (WL # 718739, 20 January 2026) - NAD+ compounded using a bulk drug substance not eligible under section 503B, adverse events in three patients, and excessive bacterial endotoxins in tested product.- US Food and Drug Administrationregulatory
- 5.ADDERALL (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, amphetamine sulfate) tablet - full prescribing information: ADHD and narcolepsy indication, Schedule II status, and mydriasis listed under eye disorders in adverse reactions.- DailyMed, National Library of Medicinelabel